Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.77 |
| ▸ | NPC1 | O15118 | 11/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | TP53 | P04637 | 5/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483328 | 0.93 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL6799157 | 0.88 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL30341896 | 0.83 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL2919439 | 0.83 | RAB9A (0.87) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL22192206 | 0.83 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL8770881 | 0.83 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL8769709 | 0.83 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL6361263 | 0.83 | RAB9A (0.89) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL7304276 | 0.82 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2TP53ALOX15 | |
| SCHEMBL7301192 | 0.82 | NPC1 (0.81) | RAB9ANPC1SMN1; SMN2TP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | claimed |
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | claimed |
| US-9546163-B2 | 3,5-diaminopyrazole kinase inhibitors | AXIKIN PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| WO-2016106309-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | AXIKIN PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | claimed |
| CN-100534990-C | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | claimed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | claimed |
| CN-1610678-A | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS LTD (CH) | 2005-04-27 | — | — | CN | claimed |
| EP-1463724-A1 | PYRROLIDONE CARBOXAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-06 | — | — | EP | claimed |
| WO-2003059905-A1 | PYRROLIDONE CARBOXAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-24 | — | — | WO | claimed |
| CN-107250116-B | 3, 5-diaminopyrazole kinase inhibitors | 艾士盟医疗公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3237407-B1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | SMA THERAPEUTICS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3237407-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | Axikin Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9730914-B2 | 3,5-diaminopyrazole kinase inhibitors | Axikin Pharmaceuticals (US) | 2017-08-15 | — | — | US | disclosed |
| EP-1463724-A1 | PYRROLIDONE CARBOXAMIDES | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003059905-A1 | PYRROLIDONE CARBOXAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-24 | — | — | WO | disclosed |
| US-6469003-B1 | COMPOUNDS HAVING CELL ADHESION INHIBITING ACTIVITY | NIHON NOHYAKU CO., LTD. (JP) | 2002-10-22 | — | — | US | disclosed |
| CN-1323297-A | Pyridazinone derivatives | NIHON NOHYAKU CO LTD (JP) | 2001-11-21 | — | — | CN | disclosed |
| EP-1130015-A1 | PYRIDAZINONE DERIVATIVES | Nihon Nohyaku Co., Ltd. (JP) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087131-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | RAB9A 2122/4885NPC1 2748/4885SMN1; SMN2 3916/4885 |
| US-20160176857-A1 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS | MAP3K13, MAP3K3, PRKAG3 | RAB9A 2122/4885NPC1 2748/4885SMN1; SMN2 3916/4885 |
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | RAB9A 3133/4885NPC1 4071/4885SMN1; SMN2 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.